[Benign prostatic hyperplasia: medical therapy]
- PMID: 17912863
[Benign prostatic hyperplasia: medical therapy]
Abstract
Primary aims of the medical therapy for BPH are improvement of subjective symptoms and quality of life as well as the prevention of long-term complications such as acute urinary retention and renal failure. Secondary goal is inhibition of disease progression. The medical therapy should be tailored to each patient according to the individual complaints and risk of progression. Plant extracts, alpha-blockers and 5-alpha reductase inhibitors represent the most common prescribed substances. Recent data suggest beneficial effects for the use of antimuscarinic agents and phosphodiesterase type 5 inhibitors.
Similar articles
-
[5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].MMW Fortschr Med. 2002 Oct 31;144(44):56. MMW Fortschr Med. 2002. PMID: 12494605 German. No abstract available.
-
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].Aktuelle Urol. 2004 Sep;35(5):339-42. doi: 10.1055/s-2004-834352. Aktuelle Urol. 2004. PMID: 15383991 German. No abstract available.
-
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656. N Engl J Med. 2003. PMID: 14681504 Clinical Trial.
-
The role of combination medical therapy in benign prostatic hyperplasia.Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Int J Impot Res. 2008. PMID: 19002123 Review.
-
A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.Clin Ther. 2007 Jan;29(1):17-25. doi: 10.1016/j.clinthera.2007.01.018. Clin Ther. 2007. PMID: 17379044 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical